0
Signin
countryflagCA

888-969-2592

RY 156.04 -0.032% TD 79.81 -0.4615% SHOP 99.81 0.9303% CNR 158.79 0.6401% ENB 53.84 0.4478% CP 111.87 0.8019% BMO 112.71 0.7419% TRI 225.62 0.396% CNQ 50.46 2.4777% BN 67.8 1.194% ATD 76.93 -1.0674% CSU 4321.5298 0.3257% BNS 67.27 1.3102% CM 78.76 1.5603% SU 54.66 -1.1037% TRP 62.42 1.2162% NGT 70.54 0.2558% WCN 251.32 0.3153% MFC 36.65 -0.0818% BCE 47.21 0.3187%

Insulet Corporation

Healthcare US PODD

202.77USD
-2.38(1.16%)

Last update at 2024-08-30T20:00:00Z

Day Range

201.15209.22
LowHigh

52 Week Range

125.82298.95
LowHigh

Fundamentals

  • Previous Close 205.15
  • Market Cap12454.43M
  • Volume605838
  • P/E Ratio53.40
  • Dividend Yield-%
  • EBITDA339.40M
  • Revenue TTM1780.70M
  • Revenue Per Share TTM25.50
  • Gross Profit TTM 805.60M
  • Diluted EPS TTM3.33

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 9.80M 20.50M 9.70M 14.50M 5.23M
Minority interest - - - - -
Net income 4.60M 16.80M 6.80M 11.60M 3.29M
Selling general administrative 587.80M 466.00M 384.00M 115.50M 111.82M
Selling and marketing expenses - - - 185.10M 142.32M
Gross profit 805.60M 752.10M 582.30M 480.30M 370.17M
Reconciled depreciation 63.20M 57.40M 55.40M 27.90M 15.65M
Ebit -26.70000M 66.70M -0.60000M 22.10M 11.78M
Ebitda 36.50M 124.10M 54.80M 50.00M 27.42M
Depreciation and amortization 63.20M 57.40M 55.40M 27.90M 15.65M
Non operating income net other -1.10000M -44.30000M 3.30M -0.90000M 6.71M
Operating income -26.70000M 66.70M -0.60000M 22.10M 27.42M
Other operating expenses 1267.70M 972.80M 852.90M 688.20M 536.40M
Interest expense 26.70M 61.20M 45.10M 26.80M 22.20M
Tax provision 5.20M 3.70M 2.90M 2.90M 1.93M
Interest income 9.80M 0.50M 3.00M 7.80M 6.71M
Net interest income -26.70000M -61.20000M -45.10000M -26.80000M -22.19700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.20M 3.70M 2.90M 2.90M 1.93M
Total revenue 1305.30M 1098.80M 904.40M 738.20M 563.82M
Total operating expenses 768.00M 626.10M 530.80M 430.30M 342.75M
Cost of revenue 499.70M 346.70M 322.10M 257.90M 193.66M
Total other income expense net 36.50M -46.20000M 10.30M -7.60000M -22.19700M
Discontinued operations - - - - -
Net income from continuing ops 4.60M 16.80M 6.80M 11.60M 3.29M
Net income applicable to common shares 4.60M 16.80M 6.80M 11.60M 3.29M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2588.20M 2251.10M 2048.80M 1872.90M 1142.90M
Intangible assets 98.70M 75.50M 36.60M 28.70M 13.20M
Earning assets - - - - -
Other current assets 99.80M 86.90M 74.00M 63.00M 31.10M
Total liab 1855.50M 1774.70M 1492.50M 1269.30M 1067.00M
Total stockholder equity 732.70M 476.40M 556.30M 603.60M 75.90M
Deferred long term liab - 31.30M 26.10M 21.90M 19.90M
Other current liab 363.70M 306.40M 166.00M 138.10M 103.20M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings -378.00000M -584.30000M -649.50000M -666.30000M -672.00000M
Other liab - 8.30M 14.90M 17.80M 7.00M
Good will 51.70M 51.70M 39.80M 39.80M 39.80M
Other assets 0.00000M 147.10M 106.10M 79.00M 25.00M
Cash 650.70M 674.70M 791.60M 947.60M 376.10M
Cash and equivalents - - - - -
Total current liabilities 451.20M 364.70M 228.80M 207.80M 157.70M
Current deferred revenue 15.40M - - - -
Net debt 798.10M 727.10M 457.20M 96.10M 511.80M
Short term debt 52.90M 27.50M 25.10M 15.60M -
Short long term debt 49.40M 27.50M 25.10M 15.60M -
Short long term debt total 1448.80M 1401.80M 1248.80M 1043.70M 887.90M
Other stockholder equity 1102.60M 1040.60M 1207.90M 1264.30M 749.00M
Property plant equipment - 599.90M 536.50M 478.70M 399.40M
Total current assets 1566.30M 1314.00M 1329.80M 1248.70M 591.00M
Long term investments - - - 0.00000M 58.40M
Net tangible assets - 349.20M 479.90M 535.10M 22.90M
Short term investments 53.50M - 0.00000M 40.40M 162.40M
Net receivables 359.70M 205.60M 161.00M 83.80M 82.80M
Long term debt 1366.40M 1374.30M 1248.80M 1043.70M 887.90M
Inventory 402.60M 346.80M 303.20M 154.30M 101.00M
Accounts payable 19.20M 30.80M 37.70M 54.10M 54.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 8.00M 20.00M -2.20000M 5.50M -1.20000M
Additional paid in capital - - - - -
Common stock total equity - 0.10M 0.10M 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - -584.30000M -649.50000M -666.30000M -672.00000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 178.70M 210.00M 106.10M 77.00M 41.10M
Deferred long term asset charges - - - - -
Non current assets total 1021.90M 937.10M 719.00M 624.20M 551.90M
Capital lease obligations - - - - -
Long term debt total - 1374.30M 1248.80M 1043.70M 887.90M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -176.20000M -7.80000M 40.00M 180.50M 97.30M
Change to liabilities - 131.50M 8.80M 34.90M 41.30M
Total cashflows from investing activities - -191.10000M -82.70000M 14.00M -73.60000M
Net borrowings - -39.80000M -464.90000M 128.30M 31.20M
Total cash from financing activities -13.60000M -40.30000M 40.70M 605.50M 73.50M
Change to operating activities - 100.80M -22.30000M -4.40000M -16.80000M
Net income 206.30M 4.60M 16.80M 6.80M 11.60M
Change in cash 26.80M -116.70000M -115.60000M 708.30M 99.80M
Begin period cash flow 623.90M 806.40M 922.00M 213.70M 113.90M
End period cash flow 650.70M 689.70M 806.40M 922.00M 213.70M
Total cash from operating activities 145.40M 119.00M -68.10000M 84.00M 98.40M
Issuance of capital stock - 0.00000M 0.00000M 477.50M 50.90M
Depreciation 72.80M 63.20M 57.40M 55.40M 27.90M
Other cashflows from investing activities - -60.40000M -10.80000M -37.50000M -7.20000M
Dividends paid 10.60M - 23.50M 98.50M 8.60M
Change to inventory -53.60000M -49.10000M -154.40000M -50.50000M -30.20000M
Change to account receivables -154.20000M -51.80000M -71.30000M -15.60000M -10.90000M
Sale purchase of stock -13.20000M -16.80000M -28.20000M -29.80000M -8.60000M
Other cashflows from financing activities 26.60M 16.30M -28.20000M 384.60M 703.40M
Change to netincome - 47.90M 81.10M 40.00M 43.00M
Capital expenditures 109.20M 157.30M 122.70M 166.50M 170.90M
Change receivables - -51.80000M -71.30000M -15.60000M -
Cash flows other operating - -33.10000M -46.70000M -32.20000M -30.80000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -112.40000M -110.10000M 703.50M 98.30M
Change in working capital -190.60000M -2.50000M -263.60000M -63.40000M -19.70000M
Stock based compensation 48.30M 40.90M 34.40M 35.90M 28.70M
Other non cash items -155.40000M 12.80M 41.40M 46.00M 36.70M
Free cash flow 36.20M -38.30000M -190.80000M -82.50000M -72.50000M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PODD
Insulet Corporation		 -2.38 1.16% 202.77 53.40 61.35 7.23 16.75 7.65 40.13
ABT
Abbott Laboratories		 0.51 0.45% 113.27 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 2.49 0.70% 360.42 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.39 0.44% 88.58 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.12 1.39% 81.79 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation

100 Nagog Park, Acton, MA, United States, 01720

Key Executives

Name Title Year Born
Dr. James R. Hollingshead Ph.D. Pres, CEO & Director 1963
Mr. Wayde D. McMillan Exec. VP,CFO & Treasurer 1970
Mr. Charles Alpuche Exec. VP & COO 1960
Mr. John Wodick Kapples Sr. VP & Gen. Counsel 1960
Ms. Shacey Petrovic Director & Advisor 1974
Mr. Bret Christensen Exec. VP & Chief Commercial Officer 1971
Ms. Lauren Budden VP, Chief Accounting Officer & Controller NA
Ms. Deborah R. Gordon CPA VP of Investor Relations 1970
Mr. Michael Spears Sr. VP of Regulatory Affairs & Compliance 1965
Angela Geryak Wiczek Sr. Director of Corp. Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.